CervoMed Inc. (NASDAQ:CRVO – Free Report) – Equities research analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for shares of CervoMed in a report issued on Wednesday, August 12th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.48) per share for the quarter, up from their previous estimate of ($0.60). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($2.50) per share. HC Wainwright also issued estimates for CervoMed’s Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($2.32) EPS, Q1 2027 earnings at ($0.46) EPS, Q2 2027 earnings at ($0.41) EPS and FY2027 earnings at ($1.90) EPS.
CervoMed (NASDAQ:CRVO – Get Free Report) last posted its earnings results on Friday, August 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.22. CervoMed had a negative return on equity of 166.00% and a negative net margin of 672.80%.
Get Our Latest Stock Analysis on CervoMed
CervoMed Stock Performance
Shares of CRVO opened at $2.93 on Friday. The firm has a market cap of $44.30 million, a P/E ratio of -0.91 and a beta of -0.63. CervoMed has a twelve month low of $2.13 and a twelve month high of $11.25. The firm’s 50 day moving average price is $3.12 and its two-hundred day moving average price is $3.75.
Hedge Funds Weigh In On CervoMed
Several hedge funds have recently modified their holdings of the stock. Rhumbline Advisers increased its position in shares of CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock valued at $53,000 after acquiring an additional 1,526 shares during the last quarter. XTX Topco Ltd bought a new position in CervoMed in the fourth quarter valued at approximately $81,000. Jane Street Group LLC bought a new position in CervoMed in the fourth quarter valued at approximately $88,000. Marshall Wace LLP acquired a new position in shares of CervoMed during the 2nd quarter worth approximately $76,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of CervoMed during the 4th quarter worth approximately $110,000. Institutional investors own 25.15% of the company’s stock.
Insider Transactions at CervoMed
In other CervoMed news, Director Joshua S. Boger purchased 955,414 shares of the stock in a transaction on Thursday, June 11th. The shares were purchased at an average cost of $3.14 per share, for a total transaction of $2,999,999.96. Following the purchase, the director owned 1,795,865 shares of the company’s stock, valued at approximately $5,639,016.10. This represents a 113.68% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 35.80% of the company’s stock.
Key Stories Impacting CervoMed
Here are the key news stories impacting CervoMed this week:
- Positive Sentiment: HC Wainwright raised multiple EPS forecasts and reaffirmed its Buy rating. The firm improved its estimates for CervoMed’s Q3 2026 EPS to $(0.48) from $(0.60), Q4 2026 to $(0.48) from $(0.59), and full-year 2026 to $(2.32) from $(2.70). It also raised its Q1 2027 estimate to $(0.46), Q2 2027 to $(0.41), and FY2027 to $(1.90) from $(1.99). These revisions imply analysts expect narrower losses than previously forecast. CervoMed analyst estimates
- Positive Sentiment: Brookline Capital Markets also reduced its projected losses. The firm raised its Q3 2026 EPS estimate to $(0.73) from $(1.04), Q4 2026 to $(0.75) from $(1.55), and FY2026 to $(2.97) from $(4.34). The revisions provide additional evidence of improving near-term earnings expectations, although Brookline’s outlook remains less optimistic than HC Wainwright’s. CervoMed analyst estimates
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating, reinforcing the favorable analyst view of CervoMed’s prospects. HC Wainwright Reaffirms Buy Rating for CervoMed
- Negative Sentiment: CervoMed is still expected to report substantial losses: the consensus forecast calls for approximately $(2.50) in EPS for the current year. The company also has a negative net margin and return on equity, so the improved estimates represent narrower losses rather than profitability.
CervoMed Company Profile
CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.
Read More
- Five stocks we like better than CervoMed
- Inside Teledyne’s Bold Bet on the Future of Medical Imaging
- Why Are Analysts Freaking Out About Apple’s All-Glass iPhone?
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
Receive News & Ratings for CervoMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CervoMed and related companies with MarketBeat.com's FREE daily email newsletter.
